Alimta approved in US for first-line use in lung cancer

Lilly's chemotherapy drug Alimta (pemetrexed) has secured its biggest approval yet in the US, for the first-line treatment of locally-advanced and metastatic non-squamous non-small cell lung cancer (NSCLC).